8-K
filed August 1, 2023, 7:59 PM ET
ticker HRMY
CIK 0001802665
earnings
confidence high
sentiment positive
materiality 0.75
Harmony Biosciences Q2 net revenue $134.2M, up 25% YoY; board approves $125M buyback
Harmony Biosciences Holdings, Inc.
2023-Q2 EPS reported
$1.05
revenue$253,342,000
- Q2 net revenue $134.2M vs $107.0M YoY (+25%); GAAP net income $34.3M ($0.56 diluted EPS).
- Non-GAAP adjusted net income $45.9M ($0.76 diluted EPS) vs $34.7M ($0.57) YoY.
- Average patients on WAKIX ~5,450, up ~350 sequentially; exited Q2 with ~5,600 patients.
- Phase 3 IH INTUNE study fully enrolled; topline data expected Q4 2023. PWS Phase 3 study to initiate Q4 2023.
- Board authorized $125M share repurchase program with no expiration date.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.
- Period
- quarter ended June 30, 2023
- Net income
- 34.3 million
- EPS
- 0.56
- Result
- reported results
Exact text from the filing
Net product revenues for the quarter ended June 30, 2023 were $134.2 million, compared to $107.0 million for the same period in 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.
- Period
- quarter ended June 30, 2023
- Net income
- 34.3 million
- EPS
- 0.56
- Result
- reported results
Exact text from the filing
GAAP net income for the quarter ended June 30, 2023, was $34.3 million, or $0.56 earnings per diluted share, compared to GAAP net income of $23.5 million, or $0.39 earnings per diluted share, for the same period in 2022.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.